Catherine Boutsikakis on The Complexities of Hemophilia
Catherine Boutsikakis, Managing Pharmacist – Patient Pharmacy at Cure 4 The Kids Foundation, shared on LinkedIn:
”Thank you Pharmacy Times for the opportunity to discuss the complexities of hemophilia, new treatments available, and the impact on patients and families.”
Watch the full discussion here.
Hemophilia is classified as mild, moderate, or severe based on clotting factor activity, which determines its clinical presentation.
Severe hemophilia is characterized by spontaneous bleeding, especially into joints and muscles, often resulting in chronic pain, limited mobility, and progressive joint damage.
Moderate hemophilia typically leads to bleeding after minor injuries, whereas mild cases usually bleed only with significant trauma or surgical procedures.
Recognizing this spectrum helps clinicians anticipate complications, individualize treatment strategies, and reduce long-term morbidity while preserving quality of life.”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
-
Jan 12, 2026, 01:45Khurram Nasir on Where The Cholesterol Guidelines Are Headed
-
Jan 12, 2026, 01:35Nirav Dhanesha Shares The Lab’s Latest Publication on Neutrophil CD14 and DVT Link
-
Jan 12, 2026, 01:07Akshat Jain Presents The New Edition of Global Sickle Cell Disease Insight Publication
-
Jan 11, 2026, 21:05Simona Sacco Shares Expert Guidance for Clinicians on Minor Ischemic Stroke
-
Jan 11, 2026, 11:00Benjamin YQ Tan on Impacts of Early Cognitive and Psychological Statuses Post-Stroke
-
Jan 11, 2026, 10:46Salvador Payán Pernía: Leukodepletion Reduces Microplastic Burden in Red Blood Cell Concentrates
-
Jan 11, 2026, 10:36Mariasanta Napolitano on Pregnancy and Delivery Outcomes in Women with Hemophilia
-
Jan 11, 2026, 10:19Quick Explanation of Types of Blood Transfusion from John Amako